<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03851731</url>
  </required_header>
  <id_info>
    <org_study_id>Naltrexone-Ph1a-001</org_study_id>
    <nct_id>NCT03851731</nct_id>
  </id_info>
  <brief_title>Evaluation of Intranasal Naltrexone and Naloxone</brief_title>
  <official_title>Pharmacokinetic Evaluation of Intranasal Naltrexone and Naloxone Administered Separately and in Combination in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be to determine the pharmacokinetics of naltrexone and naloxone when
      administered via intranasal separately and in combination in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2015</start_date>
  <completion_date type="Actual">November 7, 2015</completion_date>
  <primary_completion_date type="Actual">November 7, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameter [maximum serum concentration - Cmax]</measure>
    <time_frame>12 days</time_frame>
    <description>The primary endpoints of the study are the pharmacokinetic parameter, maximum serum concentration [Cmax], of naltrexone and naloxone when administered and in combination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter [area under the plasma concentration time curve - AUCO-t]</measure>
    <time_frame>12 days</time_frame>
    <description>The primary endpoints of the study are the pharmacokinetic parameter, area under the plasma concentration time curve [AUCO-t] of naltrexone and naloxone when administered and in combination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter [area under the plasma concentration curve from zero to infinity - AUCO-inf]</measure>
    <time_frame>12 days</time_frame>
    <description>The primary endpoints of the study are the pharmacokinetic parameter, area under the plasma concentration curve from zero to infinity [AUCO-inf] of naltrexone and naloxone when administered and in combination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>15 days</time_frame>
    <description>To assess and document any adverse events measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Sign - Heart Rate</measure>
    <time_frame>12 days</time_frame>
    <description>To assess and document heart rate before and after intranasal dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Sign - Blood pressure (diastolic)</measure>
    <time_frame>12 days</time_frame>
    <description>To assess and document blood pressure (diastolic) before and after intranasal dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Sign - Blood pressure (systolic)</measure>
    <time_frame>12 days</time_frame>
    <description>To assess and document blood pressure (systolic) before and after intranasal dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Sign - Respiration Rate</measure>
    <time_frame>12 days</time_frame>
    <description>To assess and document respiration rate before and after intranasal dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>12 days</time_frame>
    <description>Twelve-lead ECGs performed according to standard procedures that will assess P wave, PR interval, QRS complex, ST segment, T wave and QT interval.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Opioid-use Disorder</condition>
  <arm_group>
    <arm_group_label>Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject received a single intranasal dose of 2 mg naltrexone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naloxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject received a single intranasal dose of 4 mg naloxone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject received a single intranasal dose of a combination of 2 mg naltrexone and 4 mg naloxone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>Intranasal spray</description>
    <arm_group_label>Naltrexone</arm_group_label>
    <other_name>Vivitrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone</intervention_name>
    <description>Intranasal spray</description>
    <arm_group_label>Naloxone</arm_group_label>
    <other_name>Narcan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexol</intervention_name>
    <description>Intranasal spray</description>
    <arm_group_label>Naltrexol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 18 to 55 years of age, inclusive.

          -  Provide written informed consent.

          -  Body mass index (BMI) ranging from 18 to 30 kg/m2, inclusive.

          -  Adequate venous access.

          -  No clinically significant concurrent medical conditions determined by medical history,
             physical examination, clinical laboratory examination, vital signs, and 12-lead ECG.

          -  Agree to use a reliable double-barrier method of birth control from the start of
             screening until one week after completing the study. Oral contraceptives are
             prohibited.

          -  Agree not to ingest alcohol, drinks containing xanthine &gt;500 mg/day (e.g., Coca ColaÂ®,
             tea, coffee, etc.), or grapefruit/grapefruit juice or participate in strenuous
             exercise 72 hours prior to admission through the last blood draw of the study.

        Exclusion Criteria:

          -  Contact site for more information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nora Chiang, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NIH / NIDA</affiliation>
  </overall_official>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 19, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2019</study_first_posted>
  <last_update_submitted>February 21, 2019</last_update_submitted>
  <last_update_submitted_qc>February 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

